Table III.

Effect of different doses of Endostar on the survival time of S180 and H22 tumor-bearing mouse models of malignant ascites (means ± standard deviation; n=18).

Group	S180	H22
Control	12.7±1.2	11.6±0.8
4 mg/kg Endostar	13.8±1.4a	12.8±1.4a
8 mg/kg Endostar	17.2±1.5b,c	15.9±1.9b,c
16 mg/kg Endostar	16.3±2.0b	15.0±2.0b

^aP>0.05

^bP<0.05 vs. control group

^cP>0.05 vs. 16 mg/kg Endostar group.